Announcement on the Company's resolution on cash dividend
date(additional information)
Date of events
2022/06/27
To which item it meets
paragraph 14
Statement
1.Date of the resolution by the board of directors or
shareholders' meeting, or of the decision by the company:2022/06/27
2.Type (ex-rights or ex-dividend) (please write "Ex-rights",
"Ex-dividend", or "Ex-rights and dividend"):Ex-dividend
3.Type and monetary amount of dividend distribution:
Common stock cash dividend, NTD 3.5 per share, total NTD 238,802,480.
4.Ex-rights (Ex-dividend) date:2022/07/07
5.Last date before book closure:2022/07/08
6.Book closure starting date:2022/07/09
7.Book closure ending date:2022/07/13
8.Ex-rights (Ex-dividend) record date:2022/07/13
9.Deadline for applying the conversion of the debt voucher:NA
10.The closure period for the conversion of the debt voucher will
start from the date:NA
11.The closure period for the conversion of the debt voucher will
end on the date:NA
12.Payment date of cash dividend distribution:2022/08/02
13.Any other matters that need to be specified:
(1) Original type and monetary amount of dividend distribution:
Common stock cash dividend, NTD 3.5 per share, total NTD 239,827,980.
(2) Type and monetary amount of dividend distribution after change:
Common stock cash dividend, NTD 3.5 per share, total NTD 238,802,480.
(3) Reason for the change:Due to the exercise of exployee stock
warrant and the purchase of treasury stock which changes the number
of stock qualify for the dividend. The Company's Board have authorized
the chairman to keep the same cash dividend per share and change the
total amount of cash dividend distribution.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Bora Pharmaceuticals Co. Ltd. published this content on 27 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 June 2022 11:54:10 UTC.
Bora Pharmaceuticals Co Ltd is a Taiwan-based company principally engaged in the agency and sales of western medicines, as well as the research, development, manufacture and sales of new drugs and health products. The Company's main products are categorized into prescription drugs and health care products, including central nervous drugs, cardiovascular drugs, antibiotics, antiviral agents, ophthalmic drugs, gastrointestinal drugs, foam ingots and health care products. In addition, the Company has biopharmaceutical technologies related to the development of cell lines for the production of protein drugs, the development and analysis of upstream and downstream processes, as well as the establishment of quality control and testing specifications and the creation of cell banks.
BORA PHARMACEUTICALS CO., LTD. 
